22:44 , Apr 24, 2018 |  BC Innovations  |  Distillery Therapeutics

Hepatic

INDICATION: Hepatic Cell culture and mouse studies suggest PDX could help treat hepatic steatosis. In a human hepatocyte-based assay of triglyceride accumulation induced by palmitic acid, PDX decreased triglyceride levels compared with vehicle. In a...
20:35 , Feb 23, 2018 |  BC Week In Review  |  Clinical News

Roche reports Phase II data for bispecific DME candidate

Roche (SIX:ROG; OTCQX:RHHBY) reported data from the Phase II BOULEVARD trial to treat diabetic macular edema (DME) showing that once-monthly 6 mg intravitreal RG7716 for 20 weeks met the primary endpoint of improving mean best...
22:27 , Mar 16, 2017 |  BC Innovations  |  Product R&D

Neo wave

The central thesis in the increasingly hot field of neoantigens is to pick mutations from patient tumors and turn them into personalized immunotherapies. While companies are staking out their space by defining how they will...
07:00 , Sep 15, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Angiogenin ribonuclease RNase A family 5 (ANG)

Hematology INDICATION: Bone marrow transplant (BMT); poisoning Cell culture and mouse studies suggest ANG could help improve outcomes in BMT patients and treat radiation damage. In cultures of primary mouse hematopoietic stem cells (HSCs), recombinant...
07:00 , May 23, 2016 |  BioCentury  |  Product Development

Provoking a response

Gritstone Oncology Inc. selected Immune Design Corp .'s ZVex technology to deliver personalized neoantigen therapies because targeting the antigens directly to dendritic cells with a viral vector could be the most immunogenic approach. Gritstone launched...
01:45 , Nov 19, 2015 |  BC Extra  |  Company News

Genentech, Novartis to share ex-U.S. Fovista rights

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) exercised its option to share ex-U.S. rights to wet age-related macular degeneration (AMD) candidate Fovista pegpleranib with Novartis AG (NYSE:NVS; SIX:NOVN). The partners already market Lucentis ranibizumab...
07:00 , Apr 9, 2015 |  BC Innovations  |  Translation in Brief

Super-additive silencing

Tekmira Pharmaceuticals Corp. has a dual-targeting RNAi that could treat hypertriglyceridemia more effectively than therapeutics that silence either target alone. The two-component product, TKM-HTG, contains RNAi components that separately target apolipoprotein C-III ( APOC3 ;...
07:00 , Mar 9, 2015 |  BioCentury  |  Strategy

Persevering with ProstVac

After more than 20 years in clinical development, including over six years in the hands of Bavarian Nordic A/S , ProstVac rilimogene galvacirepvec found a potential commercial partner in Bristol-Myers Squibb Co. Whether BMS exercises...
01:52 , Mar 5, 2015 |  BC Extra  |  Company News

Bavarian Nordic gains on BMS option deal

Bavarian Nordic A/S (CSE:BAVA) gained DKK74.50 (35%) to DKK286 after granting Bristol-Myers Squibb Co. (NYSE:BMY) an exclusive option to license and commercialize Prostvac. The deal, which includes $60 million up front and more than $915...
08:00 , Dec 15, 2014 |  BC Week In Review  |  Company News

Alnylam pharmaceuticals news

Alnylam outlined plans to focus its RNAi pipeline on genetic medicine, cardio-metabolic diseases and hepatic infectious diseases. Clinical genetic medicine programs include Phase III transthyretin-mediated amyloidosis (ATTR) candidates patisiran and revusiran as well as Phase...